Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Metagenomi, Inc. Common Stock

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

Ionis Pharmaceuticals

Cystic Fibrosis Foundation

Sozo Ventures

Agent Capital

RA Capital Management

Leaps by Bayer

HOF Capital

Humboldt Fund

InCube Ventures

Yaya Capital

Surveyor Capital

Novo Holdings

Marshall Wace

Millennium Management

Bristol Myers Squibb

Deep Track Capital

Eventide

Farallon Capital Management

Frazier Healthcare Partners

SymBiosis LLC

Catalio Capital Management

Moderna

Metagenomi

From our team to yours, we wish you a safe and joyful holiday season. As we wind down for our annual winter break, we look forward to what’s to come in the new year.

During AIChE's 6th International Conference on CRISPR Technologies, which took place October 17-19th in Boston, MA, Metagenomi gave one oral presentation and two poster presentations.  What scientific findings did we present at this conference?

Last year, we published new data in Nature Portfolio describing novel, compact RNA-guided nucleases used to develop the smallest adenine base editor (ABE) to date. This ABE, at just 623 amino acids in size, is highly active in cells.

Metagenomi’s discovery could potentially enable novel in vivo delivery options for our precision genetic medicines. To learn more about Metagenomi's discovery platform, visit our website, and see the link below to learn more about our findings. 

Read more: https://lnkd.in/gebRnH5K

Today’s historic FDA approval of the first CRISPR-based therapy is a remarkable step forward for both sickle cell patients and the field of gene editing. We wholeheartedly celebrate this major milestone and congratulate the countless scientists and researchers dedicated to creating curative genetic medicines for patients in need.

https://lnkd.in/gWdrjeun

At Metagenomi, we believe that our values are foundational to who we are as an organization. In October we internally debuted the new set of company values that are reflective of our shared vision and commitment to excellence, and will guide us on our journey ahead.

With extensive input from our employees and executive team, we've distilled our core principles into three pillars that shape our identity:

-Driven by innovation
-Dedicated to scientific rigor
-Championed by each other

At the internal unveiling event, we celebrated our corporate values through historical recount and storytelling of Metagenomi's evolution, describing key moments that have informed our distinct culture. Check a photo from the event below, and visit https://lnkd.in/gJUhW6FJ to learn more.

Metagenomi is presenting during the 4th annual CRISPR 2.0 Congress from November 28-30th in Boston, MA. On Thursday, November 30th, Metagenomi will be giving two presentations:

Alan Brooks will be presenting ‘A Novel Type V CRISPR System With Potent Editing Activity in Mice and Non-Human Primates’ at 11:45 am ET . 

Chris Brown will be giving a talk titled ‘Enabling Rapid Discovery and Development of Next-Generation Genome Editing Tools Through Metagenomics’ at 3:45 pm ET.

Happy Thanksgiving! We're thankful for the incredible team at Metagenomi who work tirelessly every day to create poten­tial­ly cura­tive ther­a­peu­tics. 

#Metagenomi #HappyThanksgiving

At Metagenomi, our ultra-small nucle­as­es are high­ly effi­cient genome edit­ing sys­tems that have the poten­tial for exten­sive ther­a­peu­tic appli­ca­tions. We have pri­or­i­tized find­ing sys­tems to over­come the size con­straints of first gen­er­a­tion nucle­as­es. Our sys­tems are a frac­tion of the size and pack­age eas­i­ly into a sin­gle AAV for tar­get­ing organs beyond what is pos­si­ble with lipid nanopar­ti­cle delivery.

Learn more about our systems: https://lnkd.in/gyxsjbYB 

#Metagenomi

Today, the UK officially authorized the very first CRISPR-based gene editing therapy for use. This is a momentous day for our field and a huge step forward in paving the way for curative genetic medicines to become standardized treatments. Of course, this is an exciting day for the field, but moreover, its an astounding win for patients and families.

https://lnkd.in/ezKhAzkq

Today, Metagenomi announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer.

“I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi. “The talent, experience, and in-depth knowledge that Luis and Pamela bring will be instrumental in the execution of our strategy at a time when Metagenomi is rapidly advancing multiple therapeutic programs towards clinical development. I am proud of the world-class team we have assembled, driven by our passion and commitment to develop curative therapeutics for patients using our proprietary, metagenomics-derived genome editing toolbox.”

Read more about this appointment in our latest press release: https://lnkd.in/gvMuCU8h

	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue	3.35M -	3.35M 0%	4.91M 46.83%		8.66M -	11.34M 30.96%	12.36M 9.05%	12.40M 0.29%	11.16M 10.00%	20.01M 79.30%	11.51M 42.45%
cost of revenue	8.43M -	8.43M 0%	492K 94.16%							1.31M -
gross profit	-5.08M -	-5.08M 0%	4.42M 187.00%		8.66M -	11.34M 30.96%	12.36M 9.05%	12.40M 0.29%	11.16M 10.00%	18.70M 67.57%	11.51M 38.42%
selling and marketing expenses
general and administrative expenses	3.92M -	3.92M 0%			6.46M -	6.62M 2.38%	7.92M 19.67%	7.84M 1.02%	8.75M 11.63%		7.64M -
selling general and administrative expenses	3.92M -	3.92M 0%	4.07M 3.93%		6.46M -	6.62M 2.38%	7.92M 19.67%	7.84M 1.02%	8.75M 11.63%	7.24M 17.25%	7.64M 5.51%
research and development expenses	8.43M -	8.43M 0%	11.23M 33.22%		20.13M -	22.68M 12.67%	26.84M 18.32%	24.75M 7.76%	31.44M 27.00%	28.32M 9.92%	26.26M 7.29%
other expenses	-8.43M -	-8.43M 0%			-1K -	16K 1,700%	-85K 631.25%	-4K 95.29%	-50K 1,150%
cost and expenses	12.34M -	12.34M 0%	15.79M 27.91%		26.59M -	29.30M 10.17%	34.76M 18.63%	32.59M 6.22%	40.19M 23.30%	36.87M 8.26%	33.90M 8.07%
operating expenses	3.92M -	3.92M 0%	15.30M 290.55%		26.59M -	29.30M 10.17%	34.76M 18.63%	32.59M 6.22%	40.19M 23.30%	35.56M 11.52%	33.90M 4.68%
interest expense
ebitda	-8.74M -	-8.74M 0%	-10.38M 18.86%		-17.10M -	-6.10M 64.34%	-17.46M 186.37%	-15.37M 11.99%	-27.76M 80.64%	-15.55M 43.97%	-21.02M 35.14%
operating income	-9.00M -	-9.00M 0%	-10.88M 20.88%		-17.94M -	-17.96M 0.14%	-22.39M 24.67%	-20.20M 9.82%	-29.03M 43.75%	-16.86M 41.92%	-22.38M 32.73%
depreciation and amortization	261K -	261K 0%	492K 88.51%		841K -	1.01M 20.21%	1.15M 14.14%	1.20M 4.07%	1.27M 6.00%	1.31M 2.83%	1.36M 4.20%
total other income expenses net	252K -	252K 0%	1.13M 347.22%		-1K -	2.89M 288,700%	-85K 102.95%	-4K 95.29%	-50K 1,150%	3.92M 7,950%	1.50M 61.68%
income before tax	-8.75M -	-8.75M 0%	-9.75M 11.47%		-13.94M -	-11.11M 20.28%	-18.61M 67.54%	-16.57M 10.99%	-25.15M 51.79%	-12.94M 48.55%	-20.88M 61.38%
income tax expense	546K -	546K 0%	631K 15.57%		2.20M -	1.90M 13.61%	1.21M 36.46%	2.73M 126.04%	-3.93M 244.31%	-2.20M 44.10%	-2.11M 4.23%
net income	-9.29M -	-9.29M 0%	-10.38M 11.71%		-16.13M -	-13.01M 19.37%	-19.82M 52.37%	-19.29M 2.65%	-25.15M 30.34%	-10.74M 57.30%	-18.77M 74.81%
weighted average shs out	5.93M -	5.93M 0%	37.47M 531.95%		29.96M -				21.14M -	37.46M 77.22%	36.77M 1.85%
weighted average shs out dil	5.93M -	5.93M 0%	37.47M 531.95%		29.96M -				21.14M -	37.46M 77.22%	36.77M 1.85%
eps	-1.57 -	-1.57 0%	-0.28 82.17%	0 100%	-0.54 Infinity%	0 100%	0	0	-1.19 Infinity%	-0.29 75.63%	-0.51 75.86%
epsdiluted	-1.57 -	-1.57 0%	-0.28 82.17%	0 100%	-0.54 Infinity%	0 100%	0	0	-1.19 Infinity%	-0.29 75.63%	-0.51 75.86%

MGX

CO:METAGENOMI

Metagenomi

Last Close

1.82

22/11 21:00

Market Cap

162.97M

Beta: -

Volume Today

466.92K

Avg: -

Preview